Carnitine palmitoyltransferase II deficiency

Last updated
Carnitine palmitoyltransferase II deficiency
Other namesCPT-II, CPT2
Carnitine structure.png
Carnitine
Specialty Endocrinology   OOjs UI icon edit-ltr-progressive.svg

Carnitine palmitoyltransferase II deficiency, sometimes shortened to CPT-II or CPT2, is an autosomal recessively inherited genetic metabolic disorder characterized by an enzymatic defect that prevents long-chain fatty acids from being transported into the mitochondria for utilization as an energy source. The disorder presents in one of three clinical forms: lethal neonatal, severe infantile hepatocardiomuscular and myopathic.

Contents

First characterized in 1973 by DiMauro and DiMauro the adult myopathic form of this disease is triggered by physically strenuous activities and/or extended periods without food and leads to immense muscle fatigue and pain. [1] It is the most common inherited disorder of lipid metabolism affecting the skeletal muscle of adults, primarily affecting males. CPT II deficiency is also the most frequent cause of hereditary myoglobinuria.

Signs and symptoms

The three main types of carnitine palmitoyltransferase II deficiency classified on the basis of tissue-specific symptomatology and age of onset. Among the few people diagnosed with CPT2, some have unknown and/or novel mutations that place them outside these three categories while remaining positive for CPT2.[ citation needed ]

Neonatal form

The neonatal form is the least common clinical presentation of this disorder and is almost invariably fatal in rapid fashion regardless of intervention. Symptomatic onset has been documented just hours after birth to within 4 days of life. Affected newborns typically experience respiratory failure, low blood sugar, seizures, liver enlargement, liver failure, and heart enlargement with abnormal heart rhythms leading to cardiac arrest. In most cases, elements of abnormal brain and kidney development are apparent, sometimes even at prenatal ultrasound. Infants with the lethal neonatal form usually live no longer than a few months. [2] Neuronal migration defects have also been documented, to which the CNS pathology of the disorder is often attributed.[ citation needed ]

Infantile form

Symptomatic presentation usually occurs between 6 and 24 months of age, but the majority of cases have been documented in children less than 1 year of age. The infantile form involves multiple organ systems and is primarily characterized by hypoketotic hypoglycemia (recurring attacks of abnormally low levels of fat breakdown products and blood sugar) that often results in loss of consciousness and seizure activity. Acute liver failure, liver enlargement, and cardiomyopathy are also associated with the infantile presentation of this disorder. Episodes are triggered by febrile illness, infection, or fasting. Some cases of sudden infant death syndrome are attributed to infantile CPT II deficiency at autopsy. [3]

Adult form

This exclusively myopathic form is the most prevalent and least severe phenotypic presentation of this disorder. Characteristic signs and symptoms include rhabdomyolysis (breakdown of muscle fibers and subsequent release of myoglobin), myoglobinuria, recurrent muscle pain, and weakness. The myoglobin release causes the urine to be red or brown and is indicatory of damage being done to the kidneys which ultimately could result in kidney failure. [4] Muscle weakness and pain typically resolves within hours to days, and patients appear clinically normal in the intervening periods between attacks. Symptoms are most often exercise-induced, but fasting, a high-fat diet, exposure to cold temperature, sleep deprivation, or infection (especially febrile illness) can also provoke this metabolic myopathy. In a minority of cases, disease severity can be exacerbated by three life-threatening complications resulting from persistent rhabdomyolysis: acute kidney failure, respiratory insufficiency, and episodic abnormal heart rhythms. Severe forms may have continual pain from general life activity. The adult form has a variable age of onset. The first appearance of symptoms usually occurs between 6 and 20 years of age but has been documented in patients as young as 8 months as well as in adults over the age of 50. Roughly 80% cases reported to date have been male.[ citation needed ]

Biochemistry

Enzyme structure

The CPT system directly acts on the transfer of fatty acids between the cytosol and the inner mitochondrial matrix. [5] CPT II shares structural elements with other members of the carnitine acyltransferase protein family. [6] The crystal structure of rat CPT II was recently elucidated by Hsiao et al. [7] The human homolog of the CPT II enzyme shows 82.2% amino acid sequence homology with the rat protein. [8] Significant structural and functional information about CPT II has thus been derived from the crystallographic studies with the rat protein.

In addition to similarities shared by the acyltransferases, CPT II also contains a distinct insertion of 30 residues in the amino domain that forms a relatively hydrophobic protrusion composed of two alpha helices and a small anti-parallel beta sheet. [7] It has been proposed that this segment mediates the association of CPT II with the inner mitochondrial membrane. [7] Moreover, the insert might also facilitate the shuttling of palmitoylcarnitines directly into the active site of CPT II after translocation across the inner membrane by virtue of its juxtaposition to the active site tunnel of the enzyme. [7]

Catalytic mechanism

CPT II catalyzes the formation of palmitoyl-CoA from palmitoylcarnitine imported into the matrix via the acylcarnitine translocase. The catalytic core of the CPT II enzyme contains three important binding sites that recognize structural aspects of CoA, palmitoyl, and carnitine. [9]

Although kinetic studies are hindered by high substrate inhibition, strong product inhibition, very low Km values for the acyl-CoA substrates, and complex detergent effects with respect to micelle formation, [9] studies have shown that CPT II demonstrates a compulsory-order mechanism in which the enzyme must bind CoA before palmitoylcarnitine, and then the resulting product palmitoyl-CoA is the last substrate to be released from the enzyme. The carnitine binding site is made accessible by the conformational change induced in the enzyme by the binding of CoA. [9] This ordered mechanism is believed to be important so that the enzyme responds appropriately to the acylation state of the mitochondrial pool of CoA despite the fact that the concentrations of both CoA and acyl-CoA found in the matrix well exceed the measured km value of the enzyme (most CPT II will already have bound the CoA). [10]

The histidine residue (at position 372 in CPT II) is fully conserved in all members of the carnitine acyltransferase family and has been localized to the enzyme active site, likely playing a direct role in the catalytic mechanism of the enzyme. [6] A general mechanism for this reaction is believed to involve this histidine acting as a general base. More specifically, this reaction proceeds as a general base-catalyzed nucleophilic attack of the thioester of acetyl-CoA by the hydroxyl group of carnitine. [11]

Biochemical significance of disease-causing mutations

The majority of the genetic abnormalities in CPT II deficient patients affect amino acid residues somewhat removed from the active site of the enzyme. Thus, these mutations are thought to compromise the stability of the protein rather than the catalytic activity of the enzyme. [7] Theories regarding the biochemical significance of the two most common mutations are noted below:

Enzyme activity and disease severity

The clinical significance of the biochemical consequences that result from the genetic abnormalities in patients with CPT II Deficiency is a contested issue. Rufer et al. support the theory that there is an association between level of enzyme activity and clinical presentation. [13] Multiple research groups have transfected COS-1 cells with different CPT II mutations and found varying levels of reduction in enzyme activity compared with controls: Phe352Cys reduced enzyme activity to 70% of wild-type, Ser113Leu reduced enzyme activity to 34% of wild-type, and several severe mutations reduced activity to 5-10% of wild-type. [6]

However, most researchers are reluctant to accept the existence of a causal relationship between enzyme functionality and clinical phenotype. [6] Two groups [14] [15] have recently reported a limited correlation (lacking in statistical significance) between the genotypic array and the clinical severity of the phenotype in their patient cohorts. There is a need for further explorations of this topic in order to fully assess the biochemical ramifications of this enzymatic deficiency.[ citation needed ]

The rate of long-chain fatty acid oxidation in CPT II-deficient patients has been proposed to be a stronger predictor of clinical severity than residual CPT II enzyme activity. For example, one study found that although the level of residual CPT II activity in adult versus infantile onset groups overlapped, a significant decrease in palmitate oxidation was noted in the infantile group when compared to the adult group. [16] This group concluded that both the type and location of CPT2 mutation in combination with at least one secondary genetic factor modulate the long-chain fatty acid flux and, therefore, the severity of the disease. [16]

Pathophysiology

Carnitine is a hydrophilic natural substance acquired mostly through dietary meats and dairy products and is used by cells to transport hydrophobic fatty acids. [17] The "carnitine shuttle" [18] is composed of three enzymes that utilize carnitine to facilitate the import of hydrophobic long-chain fatty acids from the cytosol into the mitochondrial matrix for the production of energy via β-oxidation. [19]

Acyl-CoA from cytosol to the mitochondrial matrix.svg

Molecular genetics

Carnitine palmitoyltransferase II deficiency has an autosomal recessive pattern of inheritance. Autorecessive.svg
Carnitine palmitoyltransferase II deficiency has an autosomal recessive pattern of inheritance.

CPT II deficiency has an autosomal recessive pattern of inheritance. [14] CPT2 is the gene that encodes the CPT II enzyme, and it has been mapped to chromosomal locus 1p32. [20] This gene is composed of 5 exons that encode a protein 658 amino acids in length. [14] To date, sixty disease-causing mutations within the coding sequence of CPT2 have been reported in the literature, of which 41 are thought to result in amino acid substitutions or deletions at critical residues. [6]

Amino acid consequences of some reported mutations

  • Ser113Leu (338C>T) is the most common mild mutation observed in adult cases, it has an observed allelic frequency of 65% in adult cases, [14] and both homozygous and heterozygous cases have been documented.
  • Pro50His (149C>A) is also relatively common in the adult form, with an allelic frequency of 6.5%. [21]
  • Arg161Trp, Glu174Lys and Ile502Thr are other homozygous mild mutations associated with the adult form [6]
  • Arg151Gln and Pro227Leu are examples of severe homozygous mutations that have been associated with the mutisystemic infantile/neonatal form of the disorder. [6]
  • The 18 known severe mutations that result in prematurely truncated proteins lack residual CPT II activity are associated with the neonatal onset and are likely incompatible with life in most circumstances. [6]
  • Val368Ile and Met647Val are polymorphisms have been linked to CPT II deficiency. [6] These genetic abnormalities alone do not directly cause the disorder, but they seem to exacerbate the reduction in enzymatic efficiency when combined with one or more primary CPT2 mutations. [21]

Recent research [16] found that mutations associated with a specific disease phenotype segregated to specific exons. In this study, infantile-onset cases had mutations in exon 4 or 5 of the CPT2 gene, while adult-onset cases had at least one mutation in exon 1 and/or exon 3. This group suggested that Ser113Leu (exon 3) and Pro50His (exon 1) might confer some sort of protective advantage against the development of the severe infantile phenotype in patients predisposed to develop the adult form of the disorder, since these two mutations have never been identified in cases of compound heterozygous infantile cases. [16] In support of this theory, an independent group reported two cases where mutations that have been shown to cause the infantile (Arg151Gln) or neonatal (Arg631Cys) forms when homozygous instead were associated with the milder, adult-onset phenotype when present as compound heterozygous mutations with Ser113Leu as the second mutation. [14]

Diagnosis

Treatment

Standard of care for treatment of CPT II deficiency commonly involves limitations on prolonged strenuous activity and the following stipulations:

See also

Related Research Articles

<span class="mw-page-title-main">Carnitine</span> Amino acid active in mitochondria

Carnitine is a quaternary ammonium compound involved in metabolism in most mammals, plants, and some bacteria. In support of energy metabolism, carnitine transports long-chain fatty acids from the cytosol into mitochondria to be oxidized for free energy production, and also participates in removing products of metabolism from cells. Given its key metabolic roles, carnitine is concentrated in tissues like skeletal and cardiac muscle that metabolize fatty acids as an energy source. Generally individuals, including strict vegetarians, synthesize enough L-carnitine in vivo.

<span class="mw-page-title-main">Medium-chain acyl-coenzyme A dehydrogenase deficiency</span> Medical condition

Medium-chain acyl-CoA dehydrogenase deficiency is a disorder of fatty acid oxidation that impairs the body's ability to break down medium-chain fatty acids into acetyl-CoA. The disorder is characterized by hypoglycemia and sudden death without timely intervention, most often brought on by periods of fasting or vomiting.

<span class="mw-page-title-main">Inborn error of lipid metabolism</span> Medical condition

Numerous genetic disorders are caused by errors in fatty acid metabolism. These disorders may be described as fatty oxidation disorders or as a lipid storage disorders, and are any one of several inborn errors of metabolism that result from enzyme defects affecting the ability of the body to oxidize fatty acids in order to produce energy within muscles, liver, and other cell types.

<span class="mw-page-title-main">Carnitine palmitoyltransferase I deficiency</span> Medical condition

Carnitine palmitoyltransferase I deficiency is a rare metabolic disorder that prevents the body from converting certain fats called long-chain fatty acids(LCFA) into energy, particularly during periods without food. It is caused by a mutation in CPT1A on chromosome 11.

<span class="mw-page-title-main">Biotinidase deficiency</span> Medical condition

Biotinidase deficiency is an autosomal recessive metabolic disorder in which biotin is not released from proteins in the diet during digestion or from normal protein turnover in the cell. This situation results in biotin deficiency.

<span class="mw-page-title-main">ACADS</span> Protein-coding gene in humans

Acyl-CoA dehydrogenase, C-2 to C-3 short chain is an enzyme that in humans is encoded by the ACADS gene. This gene encodes a tetrameric mitochondrial flavoprotein, which is a member of the acyl-CoA dehydrogenase family. This enzyme catalyzes the initial step of the mitochondrial fatty acid beta-oxidation pathway. The ACADS gene associated with short-chain acyl-coenzyme A dehydrogenase deficiency.

<span class="mw-page-title-main">Palmitoylcarnitine</span> Chemical compound

Palmitoylcarnitine is an ester derivative of carnitine involved in the metabolism of fatty acids. During the tricarboxylic acid cycle (TCA), fatty acids undergo a process known as β-oxidation to produce energy in the form of ATP. β-oxidation occurs primarily within mitochondria, however the mitochondrial membrane prevents the entry of long chain fatty acids (>C10), so the conversion of fatty acids such as palmitic acid is key. Palmitic acid is brought to the cell and once inside the cytoplasm is first converted to Palmitoyl-CoA. Palmitoyl-CoA has the ability to freely pass the outer mitochondrial membrane, but the inner membrane is impermeable to the Acyl-CoA and thioester forms of various long-chain fatty acids such as palmitic acid. The palmitoyl-CoA is then enzymatically transformed into palmitoylcarnitine via the Carnitine O-palmitoyltransferase family. The palmitoylcarnitine is then actively transferred into the inner membrane of the mitochondria via the carnitine-acylcarnitine translocase. Once inside the inner mitochondrial membrane, the same Carnitine O-palmitoyltransferase family is then responsible for transforming the palmitoylcarnitine back to the palmitoyl-CoA form.

<span class="mw-page-title-main">Carnitine O-palmitoyltransferase</span>

Carnitine O-palmitoyltransferase is a mitochondrial transferase enzyme involved in the metabolism of palmitoylcarnitine into palmitoyl-CoA. A related transferase is carnitine acyltransferase.

<span class="mw-page-title-main">Carnitine palmitoyltransferase II</span> Mammalian protein found in Homo sapiens

Carnitine O-palmitoyltransferase 2, mitochondrial is an enzyme that in humans is encoded by the CPT2 gene.

<span class="mw-page-title-main">Carnitine palmitoyltransferase I</span> Protein-coding gene in the species Homo sapiens

Carnitine palmitoyltransferase I (CPT1) also known as carnitine acyltransferase I, CPTI, CAT1, CoA:carnitine acyl transferase (CCAT), or palmitoylCoA transferase I, is a mitochondrial enzyme responsible for the formation of acyl carnitines by catalyzing the transfer of the acyl group of a long-chain fatty acyl-CoA from coenzyme A to l-carnitine. The product is often Palmitoylcarnitine, but other fatty acids may also be substrates. It is part of a family of enzymes called carnitine acyltransferases. This "preparation" allows for subsequent movement of the acyl carnitine from the cytosol into the intermembrane space of mitochondria.

<span class="mw-page-title-main">HADHB</span> Protein-coding gene in the species Homo sapiens

Trifunctional enzyme subunit beta, mitochondrial (TP-beta) also known as 3-ketoacyl-CoA thiolase, acetyl-CoA acyltransferase, or beta-ketothiolase is an enzyme that in humans is encoded by the HADHB gene.

D-Bifunctional protein deficiency is an autosomal recessive peroxisomal fatty acid oxidation disorder. Peroxisomal disorders are usually caused by a combination of peroxisomal assembly defects or by deficiencies of specific peroxisomal enzymes. The peroxisome is an organelle in the cell similar to the lysosome that functions to detoxify the cell. Peroxisomes contain many different enzymes, such as catalase, and their main function is to neutralize free radicals and detoxify drugs. For this reason peroxisomes are ubiquitous in the liver and kidney. D-BP deficiency is the most severe peroxisomal disorder, often resembling Zellweger syndrome.

<span class="mw-page-title-main">Carnitine O-octanoyltransferase</span>

Carnitine O-octanoyltransferase is a member of the transferase family, more specifically a carnitine acyltransferase, a type of enzyme which catalyzes the transfer of acyl groups from acyl-CoAs to carnitine, generating CoA and an acyl-carnitine. The systematic name of this enzyme is octanoyl-CoA:L-carnitine O-octanoyltransferase. Other names in common use include medium-chain/long-chain carnitine acyltransferase, carnitine medium-chain acyltransferase, easily solubilized mitochondrial carnitine palmitoyltransferase, and overt mitochondrial carnitine palmitoyltransferase. Specifically, CROT catalyzes the chemical reaction:

<span class="mw-page-title-main">ETFA</span> Protein-coding gene in humans

The human ETFA gene encodes the Electron-transfer-flavoprotein, alpha subunit, also known as ETF-α. Together with Electron-transfer-flavoprotein, beta subunit, encoded by the 'ETFB' gene, it forms the heterodimeric electron transfer flavoprotein (ETF). The native ETF protein contains one molecule of FAD and one molecule of AMP, respectively.

<span class="mw-page-title-main">ETFB</span> Protein-coding gene in humans

The human ETFB gene encodes the Electron-transfer-flavoprotein, beta subunit, also known as ETF-β. Together with Electron-transfer-flavoprotein, alpha subunit, encoded by the 'ETFA' gene, it forms the heterodimeric Electron transfer flavoprotein (ETF). The native ETF protein contains one molecule of FAD and one molecule of AMP, respectively.

<span class="mw-page-title-main">NDUFS1</span> Protein-coding gene in the species Homo sapiens

NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (NDUFS1) is an enzyme that in humans is encoded by the NDUFS1 gene. The encoded protein, NDUFS1, is the largest subunit of complex I, located on the inner mitochondrial membrane, and is important for mitochondrial oxidative phosphorylation. Mutations in this gene are associated with complex I deficiency.

<span class="mw-page-title-main">FOXRED1</span> Protein-coding gene in the species Homo sapiens

FAD-dependent oxidoreductase domain-containing protein 1 (FOXRED1), also known as H17, or FP634 is an enzyme that in humans is encoded by the FOXRED1 gene. FOXRED1 is an oxidoreductase and complex I-specific molecular chaperone involved in the assembly and stabilization of NADH dehydrogenase (ubiquinone) also known as complex I, which is located in the mitochondrial inner membrane and is the largest of the five complexes of the electron transport chain. Mutations in FOXRED1 have been associated with Leigh syndrome and infantile-onset mitochondrial encephalopathy.

<span class="mw-page-title-main">ACAD9</span> Protein-coding gene in the species Homo sapiens

Acyl-CoA dehydrogenase family member 9, mitochondrial is an enzyme that in humans is encoded by the ACAD9 gene. Mitochondrial Complex I Deficiency with varying clinical manifestations has been associated with mutations in ACAD9.

<span class="mw-page-title-main">Fatty-acid metabolism disorder</span> Medical condition

A broad classification for genetic disorders that result from an inability of the body to produce or utilize an enzyme or transport protein that is required to oxidize fatty acids. They are an inborn error of lipid metabolism, and when it affects the muscles also a metabolic myopathy.

Combined malonic and methylmalonic aciduria (CMAMMA), also called combined malonic and methylmalonic acidemia is an inherited metabolic disease characterized by elevated levels of malonic acid and methylmalonic acid. Some researchers have hypothesized that CMAMMA might be one of the most common forms of methylmalonic acidemia, and possibly one of the most common inborn errors of metabolism. Due to being infrequently diagnosed, it most often goes undetected.

References

  1. ↑ Research, Institute of Medicine (US) Committee on Military Nutrition; Marriott, Bernadette M. (1994). The Role of Carnitine in Enhancing Physical Performance. National Academies Press (US).
  2. ↑ "Carnitine palmitoyltransferase II deficiency, lethal neonatal (Concept Id: C1833518) - MedGen - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2019-12-12.
  3. ↑ Oshima, Yuki; Yamamoto, Takuma; Ishikawa, Taisuke; Mishima, Hiroyuki; Matsusue, Aya; Umehara, Takahiro; Murase, Takehiko; Abe, Yuki; Kubo, Shin-ichi; Yoshiura, Koh-ichiro; Makita, Naomasa (2017-07-27). "Postmortem genetic analysis of sudden unexpected death in infancy: neonatal genetic screening may enable the prevention of sudden infant death". Journal of Human Genetics. 62 (11): 989–995. doi:10.1038/jhg.2017.79. ISSN   1434-5161. PMID   28747690. S2CID   1456601.
  4. ↑ Reference, Genetics Home. "CPT II deficiency". Genetics Home Reference. Retrieved 2019-12-12.
  5. ↑ Sigauke, Ellen; Rakheja, Dinesh; Kitson, Kimberly; Bennett, Michael J. (November 2003). "Carnitine Palmitoyltransferase II Deficiency: A Clinical, Biochemical, and Molecular Review". Laboratory Investigation. 83 (11): 1543–1554. doi: 10.1097/01.LAB.0000098428.51765.83 . ISSN   1530-0307. PMID   14615409.
  6. 1 2 3 4 5 6 7 8 9 10 Isackson PJ, Bennett MJ, Vladutiu GD (December 2006). "Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency". Molecular Genetics and Metabolism. 89 (4): 323–31. doi:10.1016/j.ymgme.2006.08.004. PMID   16996287.
  7. 1 2 3 4 5 6 7 8 Hsiao Y, Jogl G, Esser V, Tong L (2006). "Crystal structure of rat carnitine palmitoyltransferase II (CPT-II)". Biochem Biophys Res Commun. 346 (3): 974–80. doi:10.1016/j.bbrc.2006.06.006. PMC   2937350 . PMID   16781677.
  8. ↑ Finocchiaro G; et al. (1991). "cDNA cloning, sequence analysis, and chromosomal localization of the gene for human carnitine palmitoyltransferase". Proc. Natl. Acad. Sci. USA. 88 (2): 661–5. Bibcode:1991PNAS...88..661F. doi: 10.1073/pnas.88.2.661 . PMC   50872 . PMID   1988962.
  9. 1 2 3 Nic, Bhaird N; et al. (1993). "Comparison of the active sites of the purified carnitine acyltransferases from peroxisomes and mitochondria by using a reaction-intermediate analogue". Biochem J. 294 (3): 645–51. doi:10.1042/bj2940645. PMC   1134510 . PMID   8379919.
  10. ↑ Ramsay R; et al. (2001). "Molecular enzymology of carnitine transfer and transport". Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1546 (1): 21–43. doi:10.1016/s0167-4838(01)00147-9. PMID   11257506.
  11. ↑ Wu D; et al. (2003). "Structure of Human Carnitine Acetyltransferase: Molecular Basis For Fatty Acyl Transfer". J Biol Chem. 278 (15): 13159–65. doi: 10.1074/jbc.m212356200 . PMID   12562770.
  12. 1 2 Sigauke E; et al. (2003). "Carnitine Palmitoyltransferase II Deficiency: A Clinical, Biochemical, and Molecular Review". Laboratory Investigation. 83 (11): 1543–54. doi: 10.1097/01.LAB.0000098428.51765.83 . PMID   14615409.
  13. 1 2 Rufer A; et al. (2006). "The Crystal Structure of Carnitine Palmitoyltransferase 2 and Implications for Diabetes Treatment". Structure. 14 (4): 713–23. doi: 10.1016/j.str.2006.01.008 . PMID   16615913.
  14. 1 2 3 4 5 Corti S, Bordoni A, Ronchi D, et al. (March 2008). "Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency". Journal of the Neurological Sciences. 266 (1–2): 97–103. doi:10.1016/j.jns.2007.09.015. PMID   17936304. S2CID   25165281.
  15. ↑ Wieser T; et al. (2003). "Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients". Neurology. 60 (8): 1351–3. doi:10.1212/01.wnl.0000055901.58642.48. PMID   12707442. S2CID   14849280.
  16. 1 2 3 4 Thuillier L et al. (2003). Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency. Hum Metab, 21: 493-501.
  17. 1 2 Longo N, Amat, San Filippo C, Pasquali M (2006). "Disorders of Carnitine Transport and the Carnitine Cycle". Am J Med Genet C Semin Med Genet. 142 (2): 77–85. doi:10.1002/ajmg.c.30087. PMC   2557099 . PMID   16602102.
  18. ↑ Nelson DL and Cox MM (2005). "Fatty Acid Catabolism" in Lehninger Principles of Biochemistry, 4th Ed. New York: W.H. Freeman and Company, 631-55.
  19. ↑ Kerner J, Hoppel C (June 2000). "Fatty acid import into mitochondria". Biochim. Biophys. Acta. 1486 (1): 1–17. doi:10.1016/s1388-1981(00)00044-5. PMID   10856709.
  20. ↑ Gellera C; et al. (1994). "Assignment of the human carnitine palmitoyltransferase II gene (CPT1) to chromosome 1p32". Genomics. 24 (1): 195–7. doi:10.1006/geno.1994.1605. PMID   7896283.
  21. 1 2 3 4 Bonnefont JP; et al. (2004). "Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects". Molecular Aspects of Medicine. 25 (5–6): 495–520. doi:10.1016/j.mam.2004.06.004. PMID   15363638.
  22. ↑ Brivet M et al. (1999). Defects in activation and transport of fatty acids. J Inher Metab Dis, 22: 428-441.
  23. ↑ Rettinger A et al. (2002). Tandem Mass Spectrometric Assay for the Determination of Carnitine Palmitoyltransferase II Activity in Muscle Tissue. Analyt Biochem, 302: 246-251.
  24. 1 2 3 "NEWBORN SCREENING". www.newbornscreening.info. Retrieved 2019-12-12.
  25. 1 2 Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A, Wieser T (1993). "Carnitine Palmitoyltransferase II Deficiency". PMID   20301431.{{cite journal}}: Cite journal requires |journal= (help)

This article incorporates public domain text from The U.S. National Library of Medicine

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.